MRNA
Moderna, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +5.9% ·
share flow -4.6% ·
net new positions 0.0%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 145 | +2 | 263.41M | $18.44B | +8 | −7 |
| Q1 2026 | 147 | +3 | 253.55M | $12.87B | +6 | −4 |
| Q4 2025 | 144 | +3 | 257.18M | $7.59B | +5 | −1 |
| Q3 2025 | 18 | +1 | 165.07M | $4.26B | +2 | −2 |
| Q2 2025 | 15 | 0 | 160.48M | $4.43B | +1 | −1 |
| Q1 2025 | 12 | -2 | 69.84M | $1.98B | +1 | −3 |
| Q4 2024 | 14 | -1 | 78.84M | $3.28B | +3 | −4 |
| Q3 2024 | 14 | -2 | 62.86M | $4.20B | +2 | −4 |
| Q2 2024 | 16 | — | 65.32M | $7.75B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 41.19M | -1.2% | $1.06B | 0.0% | ▼ Trim | 2 | SEC ↗ ×6 |
| 2 | BlackRock ✦ (passive) | 29.53M | +3.2% | $762.71M | 0.0% | ▲ Add | 2 | SEC ↗ ×22 |
| 3 | Baillie Gifford ✦ | 21.85M | -1.1% | $564.30M | 0.4% | ▼ Trim | 6 | SEC ↗ ×4 |
| 4 | State Street Global Advisors ✦ (passive) | 17.11M | -0.9% | $441.92M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | Fidelity (FMR) ✦ | 12.30M | -37.4% | $317.82M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 6 | Morgan Stanley ✦ | 9.96M | — | $257.32M | 0.0% | n/c | 1 | SEC ↗ ×15 |
| 7 | Geode Capital Management ✦ (passive) | 9.25M | +4.2% | $238.48M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 7.53M | +8.2% | $194.50M | 0.3% | ▲ Add | 6 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 6.15M | -17.6% | $158.76M | 0.1% | ▼ Trim | 5 | SEC ↗ ×2 |
| 10 | Goldman Sachs Group ✦ | 3.18M | — | $82.13M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 11 | JPMorgan Chase ✦ | 2.77M | — | $71.65M | 0.0% | n/c | 1 | SEC ↗ ×24 |
| 12 | Citadel Advisors ✦ | 1.99M | +8.3% | $51.34M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 13 | Millennium Management ✦ | 1.17M | +34.3% | $30.16M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 482.87K | -22.6% | $12.47M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 15 | Marshall Wace ✦ | 265.37K | New | $6.85M | 0.0% | New | 1 | SEC ↗ |
| 16 | Bridgewater Associates ✦ | 222.21K | New | $5.74M | 0.0% | New | 1 | SEC ↗ |
| 17 | Wellington Management ✦ | 86.55K | +123.0% | $2.24M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 18 | Gotham Asset Management ✦ | 38.77K | +14.1% | $1.00M | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $6.85M | 0.0% |
| Bridgewater Associates | $5.74M | 0.0% |
Exited
| Norges Bank | $94.91M | was 0.0% |
| Renaissance Technologies | $27.70M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 717 holders, 306.78M shares, $15.39B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 40.28K sh · $5.88M
Officer · 40.29K sh · $5.81M
Officer · 15.00K sh · $2.02M
Officer · 19.84K sh · $2.67M
Officer · 3.47K sh · $485,766
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology